Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
SeraCare Life Sciences has launched three seroconversion panels that provide difficult-to-find patient samples for hepatitis B and HIV. HBV seroconversion panel PHM938 comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA-positive from the first bleed.
Randox Toxicology offers three new ELISA testing kits for the detection of sedative drugs zopiclone, zaleplon, and zolpidem, which behave similarly to benzodiazepines. Randox developed the ELISA kits for the detection of these drugs in urine and blood specimens. The zolpidem ELISA offers a limit of detection of 0.4 ng/mL in urine and 0.52 ng/mL in blood.
Dako has received FDA clearance to sell its Flex monoclonal rabbit anti-human estrogen receptor alpha, clone EP1 in the United States. The clone has been available in Europe for some time. With this diagnostic tool, breast cancer patients can be confident they are receiving effective treatment for their particular type of breast cancer.
Carl Zeiss Microscopy’s Axio Lab.A1 microscope is available for use in polarization microscopy. It is suitable for student education and routine laboratory requirements. This upright microscope suits colleges and universities, research institutes in the geosciences and mineralogy fields, and in the oil exploration industry.
Hamilton Robotics’ PCR setup Starlet automated liquid-handling system can accommodate any DNA amplification reagent kit, from simple setups and small budgets to highly demanding workflows. The workstation is suitable for gene expression, genotyping, sequencing, or mutagenesis. It was developed for different PCR types, such as endpoint-, q-, multiplex, or linear PCR.
CellaVision and Beckman Coulter have added Europe, the Middle East, and Africa to their global distribution agreement. The agreement gives Beckman Coulter a nonexclusive right to sell CellaVision’s products in hematology laboratories worldwide, except in Canada and Japan. Beckman and CellaVision have been developing their partnership since 2010, when they partnered in the United States, Latin America, and Asia-Pacific, including in China and India.
Thermo Fisher Scientific’s iCAP 7000 series ICP-OES (inductively coupled plasma optical emission spectrometer) is driven by Qtegra Intelligent Scientific Data Solution (ISDS) software. The platform, designed to streamline workflows and minimize cost per sample, facilitates trace elemental analysis in pharmaceutical, environmental, industrial, and food and beverage analysis applications.
Hardy Diagnostics’ parasite suspensions are designed for a variety of parasitology applications to provide reliable and consistent quality control results. The suspensions are microorganism preparations designed to mimic patient samples to support quality assurance programs in documenting process and detection proficiency. The suspensions can be used in the QC or validation of diagnostic test kits and methods, in microscopic examinations, in staining procedures, in proficiency testing, and for teaching purposes in educational settings.
Abbott has introduced in the European Union and other areas outside of the United States a molecular diagnostic test for the detection of influenza A/B and RSV (respiratory syncytial virus). The IMDx flu A/B and RSV assay, developed by Intelligent Medical Devices for Abbott’s m2000 molecular diagnostics analyzer, is performed on nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. It is a qualitative, reverse-transcription polymerase chain reaction test for rapid detection of influenza A/B and RSV.
SciGene and BioDot have entered into an agreement whereby BioDot would have exclusive rights to market and sell SciGene’s Little Dipper Processor for fluorescence in situ hybridization to cytogenetic labs worldwide. The instrument automates tissue and cell sample processing for a variety of cytogenetic tests. Terms of the deal were not disclosed.
